作　　者： (余苏云）; (汪思亮）; (贾琦）; (陈力川）; (陈文星）; (王爱云）; (陆茵）;

机构地区： 南京中医药大学药学院、江苏省中药药效与安全性评价重点实验室,江苏南京210023

出　　处： 《肿瘤》 2017年第8期878-882,共5页

摘　　要： 随着癌症发生率和死亡率的逐年上升,癌症已成为威胁人类健康的首要敌人,因此越来越多的研究者投入癌症发病机制及新疗法的探索之中。尽管如此,每年仍然只有屈指可数的抗癌新药通过审批,究其原因主要是绝大多数具有较好临床前效应的新药缺乏良好的临床疗效,因此合理应用及创新临床前抗肿瘤药物的评价体系,促进临床前研究与临床药效的结合与统一,就显得尤为迫切和重要。众所周知,动物癌症模型在癌症的病因和发病机制研究以及治疗评估中发挥着举足轻重的作用。本文对最为常用的小鼠癌症模型在临床前研究中的发展前景以及面临的挑战进行了探讨,并对新兴癌症模型的应用前景进行了简述,为临床前合理评价药物疗效提供参考。 Along with the increase in incidence and mortality of cancer, cancer has become a threat to human health. Therefore, more and more researchers have devoted themselves to the exploration of the pathogenesis of cancer and the related new therapies. Even so, only a few new anticancer drugs have been approved every year, the main reason is that the vast majority of new drugs has better preclinical effect but not has good clinical curative effect, so the reasonable application and innovation of preclinical evaluation system of antineoplastic drugs and the combination and unification of preclinical studies and clinical efficacy are urgent and important. It is well known that animal cancer models play an important role in the pathogenesis and treatment of cancer. This paper discusses the prospect of the most commonly used mouse models of cancer in preclinical studies and the challenges, and introduces the prospect of the new cancer models, in order to providereferences for rational evaluation of clinical efficacy of drugs.

关 键 词： 肿瘤 小鼠 模型 动物 药物评价 临床前 治疗结果